This research: Sheds light on a key mechanism of adolescent brain development. Shows how amphetamine disrupts this mechanism. Links this disruption to animal behaviors that resemble human susceptibility to addiction...
|
Latest from NIDA
Journal commentary addresses role of dentists in opioid crisis
The commentary, authored by Dr. Nora Volkow, director of the National Institute on Drug Abuse, and Dr. Martha Somerman, director of the National Institute of Dental and Craniofacial Research, both...
|
Reducing healthcare’s reliance on potentially addictive opioid pain relievers has been one of the pillars of federal efforts to reverse the opioid crisis.
|
Study casts doubt on effectiveness of e-cigs for smoking cessation
A study found no evidence that smokers who used e-cigarettes and other electronic nicotine delivery systems (ENDS) in the United States were more likely to quit smoking cigarettes than smokers...
|
2018 Avenir award recipient to study how social networks affect people who use drugs
A proposal to study how drug users who are part of social networks influence their own communities has been given the 2018 Avenir award for HIV/AIDS research by the National...
|
This week, the Food and Drug Administration (FDA) approved Epidiolex (cannabidiol, or CBD), a medication extracted from marijuana, for the treatment of two severe pediatric seizure disorders.
|
As Opioid Use Disorders Increased, Prescriptions for Treatment Did Not Keep Pace
Several effective medications are now available for treating opioid use disorder but many patients who could benefit do not receive them. Some patients who receive the medications face challenges to...
|
A revealing look at the brain on heroin
A NIDA-funded study reveals major changes in the brains of heroin users.
|
New clinician screening tool available for substance use
The National Institute on Drug Abuse (NIDA) Clinical Trials Network has unveiled a new scientifically validated, online screening tool designed to assess a patient’s risk for substance misuse and substance...
|
Training module now available for acute pain management in hospitalized adults
A case-based clinician training module designed for the evaluation of acute pain and opioid management for adults is now available through the Centers of Excellence in Pain Education (CoEPE) program...
|
Scientists discover path to better pain medicines
In this this NIDA-funded research, scientists used a novel approach to compare the cell signaling initiated by kappa opioids that produce dysphoria from those that do not.
|
Outcomes of Computerized CBT Rival Those of Clinician-Delivered CBT
This clinical trial: Found that patients who self-administered cognitive behavioral therapy (CBT) using computerized training modules reduced their drug use as much as patients who received clinician-delivered CBT, and they...
|
Analysis of insurance coverage for back pain shows missed opportunities to prescribe non-opioid medications
A comprehensive analysis of health insurance coverage of non-opioid and opioid medications to treat chronic low back pain concluded that some insurance plans have missed important opportunities to steer patients...
|
Methadone and buprenorphine reduce risk of death after opioid overdose
A National Institutes of Health-funded study found that treatment of opioid use disorder with either methadone or buprenorphine following a nonfatal opioid overdose is associated with significant reductions in opioid...
|
In Animals, Opioid Combination Shows Promise for Safer Pain Relief
This study found that: In rats, co-administration with nalfurafine reduced the dose of oxycodone required to lower pain responses in models of human chronic pain. The combination treatment generated less...
|
A Gene Links Impulsivity and Drug Use Vulnerability
This research: Identified a gene variant that promotes impulsive behavior and enhanced responses to heroin in rats. Linked the corresponding human gene variant to increased risk for impulsivity and drug...
|
Novel Compound Alleviates Hard-to-Treat Pain in Mice
A novel compound called GAT211 alleviates inflammatory and neuropathic pain in mice without producing tolerance or signs of abuse liability.
|
In spring 2018, Congress added an additional $500 million to the NIH budget to invest in science to find solutions to the opioid crisis. The funding that NIDA is receiving...
|
Special journal issue highlights ABCD brain study
The special issue is an overview of the ABCD Study and includes articles about the rationale for the study, its design and recruitment strategy, assessment protocols and neuroimaging parameters, the...
|
Too Hot And Too Cold: Dysregulation of key brain networks in people with addiction
Study suggests that brain activity is not simply too high or low in people who are addicted to drugs, but behaves differently to drug and non-drug stimuli.
|
Full survey of annual teen drug use now available with additional data
The complete volume of the 2017 Monitoring the Future Survey (MTF) teen drug use and behavior survey results is now available online with never before seen highlights about drug use...
|
Cigarette Smoking Increases the Likelihood of Drug Use Relapse
This research: Found that cigarette smoking increased the likelihood of relapse among people in recovery from substance use disorder (SUD). Suggests that helping patients quit and remain abstinent from smoking...
|
Higher rate of substance use among Native American youth on reservations
A survey comparing drug use among Native American youth living on or near reservations to a national sample of American youth found that Native American youth report substantially higher use...
|
Breathing under the influence of … fentanyl
An animal study at NIDA's intramural research labs suggests fentanyl-induced respiratory depression affects the temperature of the brain, triggering brain hypoxia and hyperglycemia.
|
Method to identify undetected drug suicides wins top NIDA Addiction Science Award
A project that identified and tested a bioinformatics program that can help identify underreported suicides linked to drug overdoses was awarded the first-place distinction at the 2018 Intel International Science...
|
This week, the Food and Drug Administration (FDA) approved lofexidine, the first medication targeted specifically to treat the physical symptoms associated with opioid withdrawal.
|
FDA approves first medication to reduce opioid withdrawal symptoms
Lofexidine, the first medication for use in reducing symptoms associated with opioid withdrawal in adults, has been approved by the U.S. Food and Drug Administration.
|
What science says about Tobacco + Marijuana + Pregnancy
A NIDA-funded study suggests that pregnant women who smoke both marijuana and cigarettes have a higher likelihood of smaller babies and increased maternal stress and aggression.
|
Study upends conventional view of opioid mechanism of action
A new discovery shows that opioids used to treat pain, such as morphine and oxycodone, produce their effects by binding to receptors inside neurons, contrary to conventional wisdom that they...
|
New data-gathering and analytic capabilities are enabling the kinds of massive, long-term studies needed to investigate genetic, environmental, and lifestyle factors that contribute to disease.
|